RxDoctor Payments Data

Gina Laginya, PA

Medical · Pittsburgh, PANPI 1073179727

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 75 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$424
  • AstraZeneca$289
  • AbbVie$261
  • GSK$217
  • Novartis$169
  • Johnson & Johnson$67
  • plus $138 from 3 others

What the payments were for

  • Food & beverage$1,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen13$424
AstraZeneca12$289
AbbVie19$261
GSK11$217
Novartis11$169
Johnson & Johnson3$67
Pfizer3$60
Lilly USA, LLC2$49
Sandoz1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,565 in reported general payments places this provider in the 75th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$22,611
Medicare patients
103
Services billed
1,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept50$370,705
Humira(Cf) PenAdalimumab36$241,201
Humira PenAdalimumab15$125,171
Xeljanz XrTofacitinib Citrate16$90,163
Cosentyx Sensoready PenSecukinumab12$86,590
ActemraTocilizumab16$76,689
OtezlaApremilast13$57,704
ProliaDenosumab25$40,570
RasuvoMethotrexate/Pf63$38,519
Hydroxychloroquine Sulfate277$18,352
OtrexupMethotrexate/Pf14$10,413
MethotrexateMethotrexate Sodium214$6,282
Colchicine57$5,242
Allopurinol323$3,262
Febuxostat24$2,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Prolia$424$98,27438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →